The protective effect by the medical timing of Valsartan-160mg in hypertensive CKD patients with proteinuria
Not Applicable
- Conditions
- hypertensive patients with chronic kidney disease
- Registration Number
- JPRN-UMIN000007369
- Lead Sponsor
- Department of Internal Medicine, Division of Nephrology, Juntendo University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. systolic BP is over 180mmHg, or diastolic BP is over 110mmHg 2. In case of severe hepatic injuries 3. nephrotic syndrome 4. the patients with pregnant or possibly pregnant 5. in case with contraindication of valsartan
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method evels of urinary protein after 12 and 24 weeks
- Secondary Outcome Measures
Name Time Method Clinic Blood pressure Home Blood pressure Ambulatory Blood pressure Estimation glomerulus filtration (eGFR) Serum potassium, serum creatinine Harmful phenomenon will be analyzed after 12 and 24 wekks